Skin Laboratory PCL (SKIN) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Skin Laboratory PCL THB 0.64, price THB 0.87, upside -26.4%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Skin Laboratory PCL for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Skin Laboratory Public Company Limited manufactures and distributes beauty products in Thailand and internationally. The company offers skincare products, beauty creams, cosmetics, and dietary supplements under the Skinsista and Dermie brand names. It sells its products through online channels and stores.
Show more
Skin Laboratory Public Company Limited manufactures and distributes beauty products in Thailand and internationally. The company offers skincare products, beauty creams, cosmetics, and dietary supplements under the Skinsista and Dermie brand names. It sells its products through online channels and stores. The company was incorporated in 2013 and is headquartered in Nonthaburi, Thailand.
Stock analysis
Skin Laboratory PCL (SKIN) currently trades at 0.8700 THB, while our model-based Fair Value estimate is 0.6400 THB, implying the stock looks roughly 35.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 1.27 THB per share, and 13 of the 22 models we run sit above the 0.8700 THB price.
Bear case: the Earnings-Based group reads lowest at 0.2500 THB, and 9 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.4900 THB (bear) to 0.8000 THB (bull), the price of 0.8700 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Skin Laboratory PCL reported revenue of 177M THB in FY2025 versus 282M THB in FY2022, a compound −14.4%/yr. Reported net income was 4.4M THB in FY2025, compounding −25.8%/yr from FY2022.
Key figures
Market cap 125M THB (≈ $3.7M) · P/S ratio 0.78 · EPS (TTM) −0.0500 THB · Dividend yield 12.7% · Net margin 2.5% · Return on equity −10.0% · Return on assets (EBIT) 13.3% · Operating margin −20.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at −26%, SKIN screens richer than that median.
Fair Value models
Bear 0.4900 THBFair Value 0.6400 THBBull 0.8000 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−22.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−18.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.6%
Dividend (yield on the price)12.7%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−15.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about −16.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−26% · Below median
Profitability
Return on assets3% · Above median
Net margin (TTM)−5% · Bottom 25%
Operating margin (TTM)−21% · Bottom 25%
Growth and dividend
Revenue growth−25% · Bottom 25%
Dividend yield (TTM)12.7% · Top 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
P/FCF0.3× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 5
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 98
DIVIDEND (yield)100· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Skin Laboratory PCL (SKIN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.6400 THB versus a price of 0.8700 THB, about −26% upside (overvalued).
What is the fair value of SKIN?
Our model-based fair value for Skin Laboratory PCL is 0.6400 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.8700 THB.
What is the quality score of SKIN?
Skin Laboratory PCL has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Skin Laboratory PCL (SKIN)?
Our model-based price target is the fair value of 0.6400 THB (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 0.4900 THB, optimistic scenario 0.8000 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Skin Laboratory PCL stock forecast for 2026?
Our models put fair value at 0.6400 THB, about −26% upside versus a price of 0.8700 THB (overvalued). Cautious scenario 0.4900 THB, optimistic scenario 0.8000 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Skin Laboratory PCL (SKIN)?
Skin Laboratory PCL reported trailing-twelve-month revenue of about 167M THB (latest available figure, as of Sep 24, 2026).
Does Skin Laboratory PCL pay a dividend?
Skin Laboratory PCL currently shows a dividend yield of about 12.73% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Skin Laboratory PCL (SKIN)?
For today's price to be fair in a discounted-cash-flow model, Skin Laboratory PCL would have to grow free cash flow by -15.5 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew -14.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SKIN use?
Our models discount Skin Laboratory PCL at 11.6 %: a base by market capitalisation (nano), country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Skin Laboratory PCL that is -15.5 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Skin Laboratory PCL (SKIN) delivered so far?
Over the past 3 years revenue at Skin Laboratory PCL grew -14.4 % a year. The price currently implies -15.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Skin Laboratory PCL (SKIN) growing?
The median revenue growth in the sector is +0.5 % a year. That is the yardstick for the growth priced into Skin Laboratory PCL (-15.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Skin Laboratory PCL (SKIN)?
The free-cash-flow yield on the price is 9.94 %: that much free cash flow Skin Laboratory PCL produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Skin Laboratory PCL (SKIN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Skin Laboratory PCL it is 0.6400 THB per share (as of Sep 24, 2026), against a price of 0.8700 THB. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Skin Laboratory PCL stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SKIN trades above its calculated fair value: price 0.8700 THB, fair value 0.6400 THB, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SKIN?
No. The price is what the market pays today (0.8700 THB); the fair value is what the company's own numbers justify (0.6400 THB). For Skin Laboratory PCL the two are 0.2300 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Skin Laboratory PCL worth?
The market values Skin Laboratory PCL at about 125M THB (market capitalisation, as of Sep 24, 2026). Per share that is 0.8700 THB; our models calculate a fair value of 0.6400 THB per share.
What do the bullish and bearish scenarios say about SKIN?
Our models span a range for Skin Laboratory PCL: cautious scenario 0.4900 THB, base 0.6400 THB, optimistic 0.8000 THB per share (as of Sep 24, 2026, price 0.8700 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Skin Laboratory PCL (SKIN)?
Balance-sheet figures for Skin Laboratory PCL (as of Sep 24, 2026): return on equity −10.0%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is SKIN from its 52-week high?
Skin Laboratory PCL trades at 0.8700 THB, about 76% below its 52-week high of 3.62 THB and 12% above the low of 0.7800 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.6400 THB is for.
Which stocks are comparable to Skin Laboratory PCL?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Skin Laboratory PCL stock attractive at the current price?
The data as of Sep 24, 2026: price 0.8700 THB, calculated fair value 0.6400 THB (−26%), Quality Score 59/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SKIN calculated?
We run Skin Laboratory PCL through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.6400 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Skin Laboratory PCL itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Skin Laboratory PCL (SKIN)?
The closing price on Sep 24, 2026 was 0.8700 THB. Our model-based fair value is 0.6400 THB, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Skin Laboratory PCL right now?
The price sits above even our optimistic bull case (0.8000 THB). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Skin Laboratory PCL
How large is the market capitalisation of Skin Laboratory PCL (SKIN)?
The market capitalisation of Skin Laboratory PCL is 125M THB (≈ $3.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Skin Laboratory PCL (SKIN)?
The price-to-sales ratio of Skin Laboratory PCL is 0.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Skin Laboratory PCL (SKIN)?
Earnings per share at Skin Laboratory PCL are −0.0500 THB. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Skin Laboratory PCL (SKIN)?
The dividend yield of Skin Laboratory PCL is 12.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Skin Laboratory PCL (SKIN)?
The net margin of Skin Laboratory PCL is 2.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Skin Laboratory PCL (SKIN)?
The return on equity (ROE) of Skin Laboratory PCL is −10.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Skin Laboratory PCL (SKIN)?
On an EBIT basis the return on assets of Skin Laboratory PCL is 13.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Skin Laboratory PCL (SKIN)?
The operating margin of Skin Laboratory PCL is −20.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Skin Laboratory PCL (SKIN)?
Revenue at Skin Laboratory PCL is growing −24.8% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Skin Laboratory PCL in the live analysis
One click puts Skin Laboratory PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
